Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors
Madison Vaccines Announces First Patient Dosed in an Expanded Combination Trial of MVI-816 Plus Keytruda® for Metastatic, Treatment-Resistant Prostate Cancer
Madison Vaccines Incorporated Expands Clinical Trial of MVI-118 for Prostate Cancer to University of Washington
